In pre-clinical studies, EGFR inhibition enhanced antigen presentation to T-cells, stimulated immunogenic apoptosis of tumor cells, boosted T-cell chemoattractants, and stimulated MHC-1 upregulation, all of which are predicted to enhance the anti-tumor immune response (68–71). This evidence concerns the gene EGFR and neoplasm.